Associated tags: Diagnosis, Acute coronary syndrome, Machine learning, Standard of care, ACS, Hospital, Infarction, Medical device, Patient, FDA, Drug Quality and Security Act, Orthopedic surgery, Elective surgery, Purdue University, Bachelor of Science, Centers for Medicare & Medicaid Services, Pharmaceutical industry, CMS, CSO, HCPCS
Retrieved on:
Thursday, November 11, 2021
Centers for Medicare & Medicaid Services,
CMS,
Medicare,
Center,
3D ultrasound,
TPT,
CEO,
Technology,
HCPCS,
Machine learning,
CSO,
Standard of care,
ACS,
Hospital,
Infarction,
Diagnosis,
Time,
Patient,
FDA,
Acute coronary syndrome,
Pharmaceutical industry,
Medical device EATONTOWN, N.J., Nov. 11, 2021 /PRNewswire/ -- Angel Medical Systems, Inc., (dba AngelMed) a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, announced today the Center for Medicare & Medicaid Services (CMS) has granted The Guardian™ implantable acute coronary syndrome (ACS) event detector a transitional pass-through (TPT) payment category and a new HCPCS C code (C1833) effective January 1, 2022 and will remain in effect for the following two to three years. The pass-through payment provides outpatient facilities with an incremental Medicare payment for procedures in which The Guardian is used.
Key Points:
- The pass-through payment provides outpatient facilities with an incremental Medicare payment for procedures in which The Guardian is used.
- "This is a seminal moment for AngelMed with the assignment of a dedicated C-code that supports our value proposition and facilitates offering The Guardian at Hospitals and ASCs," said Brad Snow, Chief Executive Officer (CEO) of AngelMed.
- "The new technology payment team provided a thorough assessment of our clinical results and the submitted public comments.
- TPT payment applies to patients with traditional Medicare.Applicability of separate additional payment is based on the hospital's contract with the patient's health plan.
Securities Exchange Act of 1934,
Leadership,
Bachelor of Science,
Machine learning,
Goal,
Standard of care,
Securities Act of 1933,
Forward-looking statement,
ACS,
Infarction,
Purdue University,
Hospital,
Elective surgery,
Diagnosis,
Orthopedic surgery,
Drug Quality and Security Act,
DBA,
Time,
Patient,
FDA,
Acute coronary syndrome,
Medical device,
Management EATONTOWN, N.J., Nov. 5, 2021 /PRNewswire/ --Angel Medical Systems, Inc., (DBA AngelMed) announced today the appointment of Mike Gillem as Chief Commercial Officer.
Key Points:
- EATONTOWN, N.J., Nov. 5, 2021 /PRNewswire/ --Angel Medical Systems, Inc., (DBA AngelMed) announced today the appointment of Mike Gillem as Chief Commercial Officer.
- Prior to joining AngelMed,Gillem servedas Chief Commercial Officer for McGinley Orthopedics where he helped introduce new, innovative technology to orthopedic surgeons and hospitals globally.
- I'm looking forward to leading these efforts as we build out a top tier commercial team to enhance the standard of care," said Mike Gillem, Chief Commercial Officer of AngelMed.
- Angel Medical Systems maintains a robust portfolio of U.S. patents pertaining to Acute Coronary Syndrome (ACS) Events.
Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.
Key Points:
- Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.
- Dr. Kaplan is a pioneer of new cardiac technologies and has played a significant role in The Guardian's commercialization.
- "The first commercial implant of The Guardian marks a pivotal advancement in cardiac care.
- The device detects impending ACS events, including silent heart attacks, and leads to earlier patient treatment," said Dr. Andrew Kaplan.
Circulatory system,
Cardiovascular system,
Medical emergencies,
Syndromes affecting the heart,
Branches of biology,
Acute coronary syndrome,
Cardiology,
Heart,
Cardiac electrophysiology,
Neuroprosthetics,
Outline of cardiology,
Cardiac stress test The AngelMed Guardian System is the world's first implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks.
Key Points:
- The AngelMed Guardian System is the world's first implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks.
- "The improved AngelMed Guardian devicewill have a meaningful effect on the current standard of patient cardiology care for ACS events.
- Angel Medical Systems maintains a robust portfolio of U.S. patents relating to detecting cardiac events, including silent heart attacks.
- Implanted monitor alerting to reduce treatment delay in patients with acute coronary syndrome events.
He will be succeeded by Brad Snow, an experienced leader in the medical device industry who has served in a variety of senior roles at several successful med-tech startups.
Key Points:
- He will be succeeded by Brad Snow, an experienced leader in the medical device industry who has served in a variety of senior roles at several successful med-tech startups.
- His previous leadership experience ranges from CEO to Commercial leader at SurgiTrac, ARAGON Surgical, Rubicor Medical, Fox Hollow Technologies, and RITA Medical Systems.
- Angel Medical Systems, Inc., is a proactive diagnostics company committed to advancing life-sustaining, personalized patient care, including the long-term management of high-risk coronary disease.
- Angel Medical Systems maintains a robust portfolio of U.S. patents relating to detecting cardiac events, including silent heart attacks.
First AngelMed Guardian patient implants in Asia Pacific for Hydrix Medical, a subsidiary of Hydrix Limited (ASX: HYD)
Key Points:
- First AngelMed Guardian patient implants in Asia Pacific for Hydrix Medical, a subsidiary of Hydrix Limited (ASX: HYD)
Four implants were carried out under the guidance of leading Cardiologist Dr. Leslie Lam
Angel Medical Systems is pleased to announce the first implant of the AngelMed Guardian device in Asia Pacific.
- Dr David Fischell, founder and Chairman of Angel Medical Systems commented, "We are very pleased with the success of these first Asia Pacific implants and excited about the large potential market opportunity.
- The successful implants follow Hydrix's announcement on March 13, 2020 that it had acquired an exclusive seven-year distribution agreement for eight Asia Pacific countries to distribute the AngelMed Guardian device, the world's first FDA approved implantable heart attack warning system.
- Gavin Coote, Hydrix Executive Chairman said, "The AngelMed Guardian implants are a significant milestone for Hydrix and Angel Medical Systems.
Medical emergencies,
Biomedical engineering,
Prosthetics,
Acute coronary syndrome,
Syndromes affecting the heart,
Implant,
Medical device,
ACS,
Medicine,
Medical specialties,
Clinical medicine EATONTOWN, N.J., July 23, 2020 /PRNewswire/ --Angel Medical Systems INC is pleased to announce the appointment of Gordie Nye as its new Chief Executive Officer.
Key Points:
- EATONTOWN, N.J., July 23, 2020 /PRNewswire/ --Angel Medical Systems INC is pleased to announce the appointment of Gordie Nye as its new Chief Executive Officer.
- Angel Medical Systems has developed the AngelMed Guardian, the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS) including heart attacks.
- "I am truly honored to join the Angel Medical Systems team as we prepare to enter our commercial phase.
- Mr. Nye entered the medical device field as the CEO of "A" Company Orthodontics, a PE-backed carve out of J&J's dental division.
EATONTOWN, N.J., Oct. 1, 2019 /PRNewswire/ --Angel Medical Systems Inc. is pleased to announce the creation of a Medical Advisory Board (MAB) coincident with the commercial release of the AngelMed Guardian System, the world's first implantable Acute Coronary Syndrome (ACS) event detector with real time patient notifications.
Key Points:
- EATONTOWN, N.J., Oct. 1, 2019 /PRNewswire/ --Angel Medical Systems Inc. is pleased to announce the creation of a Medical Advisory Board (MAB) coincident with the commercial release of the AngelMed Guardian System, the world's first implantable Acute Coronary Syndrome (ACS) event detector with real time patient notifications.
- Proposals for new product features and enhancements at the request of Angel Medical Systems Inc.
Proposals for continuing education programs specifically targeting the AngelMed Guardian System for clinicians, cardiologists, ED staff, EMT population, and patients and families.
- Angel Medical Systems, Inc. was founded in 2001 by Drs.
- Robert, Tim and David Fischell, active serial entrepreneurs and inventors of medical devices to advance life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease.
